EVALUATION OF EFFECTIVENESS, SAFETY AND ECONOMY OF MEDICINES CTS649

Description

This research group specialises in the evaluation of drug efficacy, safety and cost. In this multidisciplinary group you can find experts in digestive diseases, primary care physicians, clinical pharmacologists and health economists. They belong to the Málaga Biomedical Research Institute (IBIMA), University of Malaga, Andalusian Public Healthcare System and Center for Biomedical Network Research: hepatic and digestive diseases (CIBERehd). It is also a mentoring centre for the IUPHAR (International Union of Basic and Clinical Pharmacology; https://iuphar.org/clinical-division/mentoring-centers/) clinical pharmacology programme.

Research Topics

Drug-induced liver injury (DILI) induced by drugs, herbs, and dietary supplements.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and drug-induced steatosis (DIS).
Inflammatory bowel disease.
Health economics and rational use of drugs.
Drug safety and efficacy in primary care.
Clinical evolution and health outcomes in digestive diseases.

Scientific-Technical Services

Liver safety assessment for drugs: pharmacoepidemiological studies and artificial intelligence in the study of drug-induced liver damage.
Pharmacovigilance: design and evaluation of safety and efficacy in clinical trials.
Assessment and development of the role of medications in the onset and evolution of steatotic liver disease associated with metabolic dysfunction (MASLD).
Health Economics consulting.
Study of drug toxicity in human cell models in vitro.